/CLBIO.ST
CLBIO.ST Stock - Corline Biomedical AB
Healthcare|BiotechnologySTO
$16.35+0.31%
+$0.05 (+0.31%) • Dec 23
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.59
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $17.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CLBIO.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$16.19 – $16.51
TARGET (TP)$18.80
STOP LOSS$15.04
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.35
52W High$27.20
52W Low$7.90
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.78M | $25.03M | $23.55M | $7.06M | $3.70M |
| Gross Profit | $13.44M | $28.38M | $22.73M | $9.10M | $10.32M |
| Gross Margin | 137.5% | 113.4% | 96.5% | 128.9% | 279.2% |
| Operating Income | $-23,166,000 | $-1,788,000 | $2.33M | $-6,909,000 | $-7,287,000 |
| Net Income | $-23,194,000 | $-1,809,000 | $2.33M | $-6,916,000 | $-7,287,000 |
| Net Margin | -237.3% | -7.2% | 9.9% | -97.9% | -197.2% |
| EPS | $-1.06 | $-0.08 | $0.11 | $-0.34 | $-0.42 |
Company Overview
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; CHC, which is used for the treatment of soft tissue injuries; medical devices; and CHS, a coronary stent. The company was founded in 1991 and is based in Uppsala, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
CLBIO.STBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.13
Q3 2025
EPS Surprise History
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 16, 2026 | — | — | — | — |
Q4 2025 | Nov 18, 2025 | — | — | — | — |
Q3 2025 | Aug 26, 2025 | — | $-0.13 | — | — |
Q2 2025 | May 8, 2025 | — | $-0.13 | — | — |
Q1 2025 | Feb 17, 2025 | — | $-0.62 | — | — |
Q4 2024 | Nov 7, 2024 | — | $-0.14 | — | — |
Q3 2024 | Aug 23, 2024 | — | $-0.20 | — | — |
Q2 2024 | Apr 30, 2024 | — | $-0.08 | — | — |
Q1 2024 | Feb 14, 2024 | — | $-0.03 | — | — |
Q4 2023 | Nov 10, 2023 | — | $0.01 | — | — |
Q3 2023 | Aug 25, 2023 | — | $-0.11 | — | — |
Q2 2023 | Apr 28, 2023 | — | $0.05 | — | — |
Q1 2023 | Feb 24, 2023 | — | $0.02 | — | — |
Q4 2022 | Nov 25, 2022 | — | $0.09 | — | — |
Q3 2022 | Aug 23, 2022 | — | $0.04 | — | — |
Q2 2022 | May 9, 2022 | — | $-0.04 | — | — |
Q1 2022 | Feb 24, 2022 | — | $-0.06 | — | — |
Q4 2021 | Nov 25, 2021 | — | $-0.10 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.10 | — | — |
Latest News
Loading news...
Frequently Asked Questions about CLBIO.ST
What is CLBIO.ST's current stock price?
Corline Biomedical AB (CLBIO.ST) is currently trading at $16.35 per share. The stock has moved +0.31% today.
What is the analyst price target for CLBIO.ST?
No analyst price targets are currently available for this stock.
What sector is Corline Biomedical AB in?
Corline Biomedical AB operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is CLBIO.ST's market cap?
Corline Biomedical AB has a market capitalization of $0.40 billion, making it a small-cap company.
Does CLBIO.ST pay dividends?
No, Corline Biomedical AB does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACE.ST
Ascelia Pharma AB (publ)
$3.17
Mkt Cap: $0.4B
BACTI-B.ST
Bactiguard Holding AB (publ)
$19.40
Mkt Cap: $0.7B
BIOWKS.ST
Bio-Works Technologies AB (publ)
$2.25
Mkt Cap: $0.2B
ELIC.ST
Elicera Therapeutics AB (publ)
$5.59
Mkt Cap: $0.3B
ENZY.ST
Enzymatica AB (publ)
$1.91
Mkt Cap: $0.5B
FLUO.ST
FluoGuide A/S
$36.20
Mkt Cap: $0.5B
IMMU.ST
Mendus AB (publ)
$5.30
Mkt Cap: $0.3B
IVACC.ST
Intervacc AB (publ)
$0.92
Mkt Cap: $0.3B
MAGLE.ST
Magle Chemoswed Holding AB (publ)
$17.20
Mkt Cap: $0.4B
XINT.ST
Xintela AB (publ)
$0.27
Mkt Cap: $0.2B
Explore stocks similar to CLBIO.ST for comparison